| Year |
Citation |
Score |
| 2022 |
Martínez-Peña F, Pearson AD, Tang EL, Kuburich NA, Mani SA, Schultz PG, Bollong MJ, Lairson LL. Synthesis and biological evaluation of novel FiVe1 derivatives as potent and selective agents for the treatment of mesenchymal cancers. European Journal of Medicinal Chemistry. 242: 114638. PMID 36001933 DOI: 10.1016/j.ejmech.2022.114638 |
0.733 |
|
| 2017 |
Bollong MJ, Pietilä M, Pearson AD, Sarkar TR, Ahmad I, Soundararajan R, Lyssiotis CA, Mani SA, Schultz PG, Lairson LL. A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers. Proceedings of the National Academy of Sciences of the United States of America. PMID 29087350 DOI: 10.1073/Pnas.1716009114 |
0.675 |
|
| 2017 |
Yu S, Pearson A, Lim R, Rodgers D, Li S, Parker H, Weglarz M, Hampton E, Bollong M, Shen J, Zumbaldo C, Wang D, Woods A, Wright T, Schultz P, et al. P-262 A PDE4 Inhibitor-antibody Conjugate for Treating Ulcerative Colitis Inflammatory Bowel Diseases. 23. DOI: 10.1097/01.Mib.0000512805.98510.C0 |
0.604 |
|
| 2016 |
Yu S, Pearson AD, Lim RK, Rodgers DT, Li S, Parker HB, Weglarz M, Hampton EN, Bollong MJ, Shen J, Zambaldo C, Wang D, Woods AK, Wright TM, Schultz PG, et al. Targeted delivery of an anti-inflammatory PDE4 inhibitor to immune cells via an antibody-drug conjugate. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 27731313 DOI: 10.1038/Mt.2016.175 |
0.557 |
|
| 2015 |
Pearson AD, Mills JH, Song Y, Nasertorabi F, Han GW, Baker D, Stevens RC, Schultz PG. Transition states. Trapping a transition state in a computationally designed protein bottle. Science (New York, N.Y.). 347: 863-7. PMID 25700516 DOI: 10.1126/Science.Aaa2424 |
0.638 |
|
| 2014 |
Pearson AD, Williams RM. Synthetic studies towards Zetekitoxin AB: preparation of 4,5-epi-11-hydroxy-saxitoxinol. Tetrahedron. 70: 7942-7949. PMID 25313264 DOI: 10.1016/J.Tet.2014.08.058 |
0.425 |
|
| 2013 |
Barone G, Anderson J, Pearson AD, Petrie K, Chesler L. New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5814-21. PMID 23965898 DOI: 10.1158/1078-0432.Ccr-13-0680 |
0.493 |
|
| 2012 |
Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, Pei D, Sharma B, Vetharoy WR, Hallsworth A, Ahmad Z, Barker K, Moreau L, Webber H, Wang W, ... ... Pearson AD, et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 22: 117-30. PMID 22789543 DOI: 10.1016/J.Ccr.2012.06.001 |
0.426 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2014 |
Al-Saffar NM, Marshall LV, Jackson LE, Balarajah G, Eykyn TR, Agliano A, Clarke PA, Jones C, Workman P, Pearson AD, Leach MO. Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma. Plos One. 9: e103835. PMID 25084455 DOI: 10.1371/journal.pone.0103835 |
0.267 |
|
| 2012 |
Moore AS, Faisal A, Gonzalez de Castro D, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Mair D, Mirabella F, Swansbury J, Pearson AD, Workman P, Blagg J, et al. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia. 26: 1462-70. PMID 22354205 DOI: 10.1038/Leu.2012.52 |
0.261 |
|
| 2011 |
Podesta JE, Sugar R, Squires M, Linardopoulos S, Pearson AD, Moore AS. Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia. Leukemia Research. 35: 1273-5. PMID 21665275 DOI: 10.1016/j.leukres.2011.05.022 |
0.257 |
|
| 2003 |
Lovat PE, Ranalli M, Corazzari M, Raffaghello L, Pearson AD, Ponzoni M, Piacentini M, Melino G, Redfern CP. Mechanisms of free-radical induction in relation to fenretinide-induced apoptosis of neuroblastoma. Journal of Cellular Biochemistry. 89: 698-708. PMID 12858336 DOI: 10.1002/jcb.10551 |
0.254 |
|
| 2014 |
Barone G, Tweddle DA, Shohet JM, Chesler L, Moreno L, Pearson AD, Van Maerken T. MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance. Current Drug Targets. 15: 114-23. PMID 24387312 DOI: 10.2174/13894501113149990194 |
0.248 |
|
| 2016 |
Frappaz D, Federico SM, Pearson AD, Gore L, Macy ME, DuBois SG, Aerts I, Iannone R, Geschwindt R, Van Schanke A, Wang R, Geoerger B. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. European Journal of Cancer (Oxford, England : 1990). 62: 9-17. PMID 27185573 DOI: 10.1016/j.ejca.2016.03.084 |
0.248 |
|
| 2010 |
Moore AS, Blagg J, Linardopoulos S, Pearson AD. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia. 24: 671-8. PMID 20147976 DOI: 10.1038/Leu.2010.15 |
0.247 |
|
| 2002 |
Lovat PE, Oliverio S, Ranalli M, Corazzari M, Rodolfo C, Bernassola F, Aughton K, Maccarrone M, Hewson QD, Pearson AD, Melino G, Piacentini M, Redfern CP. GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of neuroblastoma. Cancer Research. 62: 5158-67. PMID 12234979 |
0.236 |
|
| 2004 |
Lovat PE, Di Sano F, Corazzari M, Fazi B, Donnorso RP, Pearson AD, Hall AG, Redfern CP, Piacentini M. Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. Journal of the National Cancer Institute. 96: 1288-99. PMID 15339967 DOI: 10.1093/jnci/djh254 |
0.23 |
|
| 2015 |
Hirsch S, Marshall LV, Carceller Lechon F, Pearson AD, Moreno L. Targeted approaches to childhood cancer: progress in drug discovery and development. Expert Opinion On Drug Discovery. 10: 483-95. PMID 25840490 DOI: 10.1517/17460441.2015.1025745 |
0.224 |
|
| 2013 |
Renshaw J, Taylor KR, Bishop R, Valenti M, De Haven Brandon A, Gowan S, Eccles SA, Ruddle RR, Johnson LD, Raynaud FI, Selfe JL, Thway K, Pietsch T, Pearson AD, Shipley J. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5940-51. PMID 23918606 DOI: 10.1158/1078-0432.CCR-13-0850 |
0.211 |
|
| 2011 |
Moreno L, Chesler L, Hargrave D, Eccles SA, Pearson AD. Preclinical drug development for childhood cancer. Expert Opinion On Drug Discovery. 6: 49-64. PMID 22646826 DOI: 10.1517/17460441.2011.537652 |
0.209 |
|
| 2010 |
Gaspar N, Marshall L, Perryman L, Bax DA, Little SE, Viana-Pereira M, Sharp SY, Vassal G, Pearson AD, Reis RM, Hargrave D, Workman P, Jones C. MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature. Cancer Research. 70: 9243-52. PMID 20935218 DOI: 10.1158/0008-5472.CAN-10-1250 |
0.206 |
|
| 2003 |
Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C, Lunec J. The p53 pathway and its inactivation in neuroblastoma. Cancer Letters. 197: 93-8. PMID 12880966 |
0.205 |
|
| 2016 |
Pearson AD, Herold R, Rousseau R, Copland C, Bradley-Garelik B, Binner D, Capdeville R, Caron H, Carleer J, Chesler L, Geoerger B, Kearns P, Marshall LV, Pfister SM, Schleiermacher G, et al. Implementation of mechanism of action biology-driven early drug development for children with cancer. European Journal of Cancer (Oxford, England : 1990). 62: 124-131. PMID 27258969 DOI: 10.1016/J.Ejca.2016.04.001 |
0.196 |
|
| 2003 |
Lovat PE, Oliverio S, Corazzari M, Ranalli M, Pearson AD, Melino G, Piacentini M, Redfern CP. Induction of GADD153 and Bak: novel molecular targets of fenretinide-induced apoptosis of neuroblastoma. Cancer Letters. 197: 157-63. PMID 12880976 DOI: 10.1016/S0304-3835(03)00098-3 |
0.196 |
|
| 2015 |
Smith JR, Moreno L, Heaton SP, Chesler L, Pearson AD, Garrett MD. Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma. Molecular Oncology. PMID 26686971 DOI: 10.1016/J.Molonc.2015.11.005 |
0.194 |
|
| 2007 |
Chen L, Malcolm AJ, Wood KM, Cole M, Variend S, Cullinane C, Pearson AD, Lunec J, Tweddle DA. p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle (Georgetown, Tex.). 6: 2685-96. PMID 17912039 |
0.188 |
|
| 2010 |
Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, Board JR, Evans L, Cole M, Cheung NK, Boos J, Köhler G, Leuschner I, Pearson AD, Lunec J, Tweddle DA. High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 1108-18. PMID 20145180 DOI: 10.1158/1078-0432.Ccr-09-1865 |
0.183 |
|
| 2003 |
Corazzari M, Lovat PE, Oliverio S, Pearson AD, Piacentini M, Redfern CP. Growth and DNA damage-inducible transcription factor 153 mediates apoptosis in response to fenretinide but not synergy between fenretinide and chemotherapeutic drugs in neuroblastoma. Molecular Pharmacology. 64: 1370-8. PMID 14645667 DOI: 10.1124/mol.64.6.1370 |
0.177 |
|
| 2003 |
Veal GJ, Errington J, Sludden J, Griffin MJ, Price L, Parry A, Hale J, Pearson AD, Boddy AV. Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 795: 237-43. PMID 14522028 |
0.176 |
|
| 2009 |
Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stávale JN, Al-Sarraj S, Reis RM, Vassal G, Pearson AD, et al. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5753-61. PMID 19737945 DOI: 10.1158/1078-0432.CCR-08-3210 |
0.164 |
|
| 2006 |
Carr J, Bell E, Pearson AD, Kees UR, Beris H, Lunec J, Tweddle DA. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Research. 66: 2138-45. PMID 16489014 DOI: 10.1158/0008-5472.CAN-05-2623 |
0.164 |
|
| 2015 |
Schrey D, Vaidya SJ, Levine D, Pearson AD, Moreno L. Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma. Journal of Pediatric Hematology/Oncology. 37: e150-3. PMID 26201036 DOI: 10.1097/MPH.0000000000000308 |
0.163 |
|
| 2005 |
Armstrong JL, Ruiz M, Boddy AV, Redfern CP, Pearson AD, Veal GJ. Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. British Journal of Cancer. 92: 696-704. PMID 15714209 DOI: 10.1038/sj.bjc.6602398 |
0.15 |
|
| 2016 |
Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. European Journal of Cancer (Oxford, England : 1990). 65: 1-10. PMID 27434878 DOI: 10.1016/j.ejca.2016.06.005 |
0.142 |
|
| 2015 |
Moreno L, Marshall LV, Pearson AD, Morland B, Elliott M, Campbell-Hewson Q, Makin G, Halford SE, Acton G, Ross P, Kazmi-Stokes S, Lock V, Rodriguez A, Lyons JF, Boddy AV, et al. A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a cancer research UK study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 267-73. PMID 25370467 DOI: 10.1158/1078-0432.CCR-14-1592 |
0.14 |
|
| 2006 |
Cole M, Boddy AV, Kearns P, Teh KH, Price L, Parry A, Pearson AD, Veal GJ. Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: how much do we really know? Pediatric Blood & Cancer. 46: 723-7. PMID 16007598 DOI: 10.1002/pbc.20463 |
0.139 |
|
| 2009 |
Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, Viana-Pereira M, Jones TA, Williams RD, Grigoriadis A, Vassal G, Workman P, Sheer D, Reis RM, Pearson AD, Hargrave D, et al. Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. Plos One. 4: e5209. PMID 19365568 DOI: 10.1371/journal.pone.0005209 |
0.137 |
|
| 2009 |
Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, Pearson AD, Matthay KK. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. British Journal of Cancer. 100: 1627-37. PMID 19401690 DOI: 10.1038/sj.bjc.6605029 |
0.128 |
|
| 2015 |
Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR, Valteau-Couanet D, Pearson AD, Cohn SL. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 3008-17. PMID 26304901 DOI: 10.1200/JCO.2014.59.4648 |
0.123 |
|
| 2002 |
Rana B, Veal GJ, Pearson AD, Redfern CP. Retinoid X receptors and retinoid response in neuroblastoma cells. Journal of Cellular Biochemistry. 86: 67-78. PMID 12112017 DOI: 10.1002/jcb.10192 |
0.115 |
|
| 2016 |
George SL, Falzone N, Chittenden S, Kirk SJ, Lancaster D, Vaidya SJ, Mandeville H, Saran F, Pearson AD, Du Y, Meller ST, Denis-Bacelar AM, Flux GD. Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma. Nuclear Medicine Communications. 37: 466-472. PMID 26813989 DOI: 10.1097/MNM.0000000000000470 |
0.11 |
|
| 2004 |
Lindsey JC, Lusher ME, Anderton JA, Bailey S, Gilbertson RJ, Pearson AD, Ellison DW, Clifford SC. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis. 25: 661-8. PMID 14688019 DOI: 10.1093/carcin/bgh055 |
0.108 |
|
| 2005 |
Veal GJ, Cole M, Errington J, Parry A, Hale J, Pearson AD, Howe K, Chisholm JC, Beane C, Brennan B, Waters F, Glaser A, Hemsworth S, McDowell H, Wright Y, et al. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 5893-9. PMID 16115931 DOI: 10.1158/1078-0432.CCR-04-2546 |
0.107 |
|
| 2010 |
Veal GJ, Cole M, Errington J, Pearson AD, Gerrard M, Whyman G, Ellershaw C, Boddy AV. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. Cancer Chemotherapy and Pharmacology. 65: 1057-66. PMID 19701749 DOI: 10.1007/s00280-009-1111-9 |
0.106 |
|
| 2013 |
Moore AS, Kearns PR, Knapper S, Pearson AD, Zwaan CM. Novel therapies for children with acute myeloid leukaemia. Leukemia. 27: 1451-60. PMID 23563239 DOI: 10.1038/leu.2013.106 |
0.103 |
|
| 1998 |
Yule SM, Skinner R, English MW, Cole M, Pearson AD, Lucraft HH, Craft AW. Outcome and toxicity of an Ifosfamide-based soft tissue sarcoma treatment protocol in children. The importance of local therapy. Sarcoma. 2: 171-7. PMID 18521250 DOI: 10.1080/13577149877939 |
0.101 |
|
| 2015 |
Fowkes LA, Koh DM, Collins DJ, Jerome NP, MacVicar D, Chua SC, Pearson AD. Childhood extracranial neoplasms: the role of imaging in drug development and clinical trials. Pediatric Radiology. 45: 1600-15. PMID 26045035 DOI: 10.1007/s00247-015-3342-8 |
0.099 |
|
| 2002 |
Meczes EL, Pearson AD, Austin CA, Tilby MJ. Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin. British Journal of Cancer. 86: 485-9. PMID 11875719 DOI: 10.1038/sj.bjc.6600060 |
0.096 |
|
| 2007 |
Veal GJ, Cole M, Errington J, Pearson AD, Foot AB, Whyman G, Boddy AV. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - a study of the United Kingdom Children's Cancer Study Group. British Journal of Cancer. 96: 424-31. PMID 17224928 DOI: 10.1038/sj.bjc.6603554 |
0.096 |
|
| 2002 |
Lashford LS, Thiesse P, Jouvet A, Jaspan T, Couanet D, Griffiths PD, Doz F, Ironside J, Robson K, Hobson R, Dugan M, Pearson AD, Vassal G, Frappaz D. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 4684-91. PMID 12488414 DOI: 10.1200/JCO.2002.08.141 |
0.096 |
|
| 2014 |
Jamin Y, Glass L, Hallsworth A, George R, Koh DM, Pearson AD, Chesler L, Robinson SP. Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma. Plos One. 9: e92886. PMID 24667968 DOI: 10.1371/Journal.Pone.0092886 |
0.094 |
|
| 2009 |
Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, Cohn SL, Pearson AD, Maris JM. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. British Journal of Cancer. 100: 1471-82. PMID 19401703 DOI: 10.1038/Sj.Bjc.6605014 |
0.093 |
|
| 2003 |
McManamy CS, Lamont JM, Taylor RE, Cole M, Pearson AD, Clifford SC, Ellison DW. Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. Journal of Neuropathology and Experimental Neurology. 62: 627-32. PMID 12834107 |
0.091 |
|
| 2004 |
Åastowska M, Chung YJ, Cheng Ching N, Haber M, Norris MD, Kees UR, Pearson AD, Jackson MS. Regions syntenic to human 17q are gained in mouse and rat neuroblastoma. Genes, Chromosomes & Cancer. 40: 158-63. PMID 15101050 DOI: 10.1002/gcc.20031 |
0.091 |
|
| 2006 |
Goranov BB, Campbell Hewson QD, Pearson AD, Redfern CP. Overexpression of RARgamma increases death of SH-SY5Y neuroblastoma cells in response to retinoic acid but not fenretinide. Cell Death and Differentiation. 13: 676-9. PMID 16341128 DOI: 10.1038/sj.cdd.4401824 |
0.09 |
|
| 2013 |
Moreno L, Marshall LV, Pearson AD. At the frontier of progress for paediatric oncology: the neuroblastoma paradigm. British Medical Bulletin. 108: 173-88. PMID 24211816 DOI: 10.1093/bmb/ldt033 |
0.09 |
|
| 2004 |
Tornóczky T, Kálmán E, Kajtár PG, Nyári T, Pearson AD, Tweddle DA, Board J, Shimada H. Large cell neuroblastoma: a distinct phenotype of neuroblastoma with aggressive clinical behavior. Cancer. 100: 390-7. PMID 14716776 DOI: 10.1002/cncr.20005 |
0.085 |
|
| 2003 |
Carlin S, Mairs RJ, McCluskey AG, Tweddle DA, Sprigg A, Estlin C, Board J, George RE, Ellershaw C, Pearson AD, Lunec J, Montaldo PG, Ponzoni M, van Eck-Smit BL, Hoefnagel CA, et al. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 3338-44. PMID 12960120 |
0.084 |
|
| 2004 |
Cole M, Price L, Parry A, Keir MJ, Pearson AD, Boddy AV, Veal GJ. Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokinetics. British Journal of Cancer. 90: 60-4. PMID 14710207 DOI: 10.1038/sj.bjc.6601484 |
0.079 |
|
| 2014 |
Morgenstern DA, Hargrave D, Marshall LV, Gatz SA, Barone G, Crowe T, Pritchard-Jones K, Zacharoulis S, Lancaster DL, Vaidya SJ, Chisholm JC, Pearson AD, Moreno L. Toxicity and outcome of children and adolescents participating in phase I/II trials of novel anticancer drugs: the Royal Marsden experience. Journal of Pediatric Hematology/Oncology. 36: 218-23. PMID 24322496 DOI: 10.1097/MPH.0000000000000003 |
0.079 |
|
| 2005 |
Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, Clifford SC. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7951-7. PMID 16258095 DOI: 10.1200/JCO.2005.01.5479 |
0.077 |
|
| 2016 |
Carceller F, Bautista FJ, Fowkes LA, Marshall LV, Sirvent SI, Chisholm JC, Pearson AD, Koh DM, Moreno L. Response Assessment in Paediatric Phase I Trials According to RECIST Guidelines: Survival Outcomes, Patterns of Progression and Relevance of Changes in Tumour Measurements. Pediatric Blood & Cancer. PMID 27149049 DOI: 10.1002/pbc.26039 |
0.074 |
|
| 2014 |
Pearson AD. Broadband Seismic - Has it delivered on its promise? 2nd Eage/Sbgf Workshop 2014 - Broadband Seismic: From Theory to Real Examples and the Road Ahead. |
0.074 |
|
| 2009 |
Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors. European Journal of Cancer (Oxford, England : 1990). 45: 3213-9. PMID 19850470 DOI: 10.1016/j.ejca.2009.06.032 |
0.074 |
|
| 2002 |
Veal GJ, Errington J, Redfern CP, Pearson AD, Boddy AV. Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells. Biochemical Pharmacology. 63: 207-15. PMID 11841795 DOI: 10.1016/S0006-2952(01)00844-9 |
0.074 |
|
| 2001 |
Rana B, Pearson AD, Redfern CP. RXR beta isoforms in neuroblastoma cells and evidence for a novel 3'-end transcript. Febs Letters. 506: 39-44. PMID 11591367 DOI: 10.1016/S0014-5793(01)02882-4 |
0.073 |
|
| 2013 |
Moreno L, Vaidya SJ, Pinkerton CR, Lewis IJ, Imeson J, Machin D, Pearson AD. Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience. Pediatric Blood & Cancer. 60: 1135-40. PMID 23281263 DOI: 10.1002/pbc.24452 |
0.072 |
|
| 2016 |
Carceller F, Fowkes LA, Khabra K, Moreno L, Saran F, Burford A, Mackay A, Jones DT, Hovestadt V, Marshall LV, Vaidya S, Mandeville H, Jerome N, Bridges LR, Laxton R, ... ... Pearson AD, et al. Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. Journal of Neuro-Oncology. PMID 27180091 DOI: 10.1007/s11060-016-2151-8 |
0.072 |
|
| 2001 |
Veal GJ, Dias C, Price L, Parry A, Errington J, Hale J, Pearson AD, Boddy AV, Newell DR, Tilby MJ. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 2205-12. PMID 11489793 |
0.071 |
|
| 2008 |
De Bernardi B, Mosseri V, Rubie H, Castel V, Foot A, Ladenstein R, Laureys G, Beck-Popovic M, de Lacerda AF, Pearson AD, De Kraker J, Ambros PF, de Rycke Y, Conte M, Bruzzi P, et al. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. British Journal of Cancer. 99: 1027-33. PMID 18766186 DOI: 10.1038/sj.bjc.6604640 |
0.069 |
|
| 2005 |
Willits I, Price L, Parry A, Tilby MJ, Ford D, Cholerton S, Pearson AD, Boddy AV. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. British Journal of Cancer. 92: 1626-35. PMID 15827549 DOI: 10.1038/sj.bjc.6602554 |
0.067 |
|
| 2013 |
Jamin Y, Tucker ER, Poon E, Popov S, Vaughan L, Boult JK, Webber H, Hallsworth A, Baker LC, Jones C, Koh DM, Pearson AD, Chesler L, Robinson SP. Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma. Radiology. 266: 130-40. PMID 23169794 DOI: 10.1148/Radiol.12120128 |
0.067 |
|
| 2007 |
Veal GJ, Errington J, Tilby MJ, Pearson AD, Foot AB, McDowell H, Ellershaw C, Pizer B, Nowell GM, Pearson DG, Boddy AV. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. British Journal of Cancer. 96: 725-31. PMID 17299395 DOI: 10.1038/sj.bjc.6603607 |
0.066 |
|
| 2010 |
Skinner R, Parry A, Price L, Cole M, Craft AW, Pearson AD. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose. Pediatric Blood & Cancer. 54: 983-9. PMID 20405516 DOI: 10.1002/pbc.22364 |
0.066 |
|
| 2003 |
Ambros IM, Benard J, Boavida M, Bown N, Caron H, Combaret V, Couturier J, Darnfors C, Delattre O, Freeman-Edward J, Gambini C, Gross N, Hattinger CM, Luegmayr A, Lunec J, ... ... Pearson AD, et al. Quality assessment of genetic markers used for therapy stratification. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2077-84. PMID 12775732 DOI: 10.1200/JCO.2003.03.025 |
0.064 |
|
| 2008 |
Ladenstein R, Pötschger U, Hartman O, Pearson AD, Klingebiel T, Castel V, Yaniv I, Demirer T, Dini G. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures. Bone Marrow Transplantation. 41: S118-27. PMID 18545256 DOI: 10.1038/bmt.2008.69 |
0.059 |
|
| 2004 |
Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5482-93. PMID 15328187 DOI: 10.1158/1078-0432.CCR-03-0721 |
0.059 |
|
| 2002 |
Hewson QC, Lovat PE, Pearson AD, Redfern CP. Retinoid signalling and gene expression in neuroblastoma cells: RXR agonist and antagonist effects on CRABP-II and RARbeta expression. Journal of Cellular Biochemistry. 87: 284-91. PMID 12397610 DOI: 10.1002/jcb.10310 |
0.058 |
|
| 2015 |
Bartholomew JC, Pearson AD, Stenseth NC, LeDuc JW, Hirschberg DL, Colwell RR. Building Infectious Disease Research Programs to Promote Security and Enhance Collaborations with Countries of the Former Soviet Union. Frontiers in Public Health. 3: 271. PMID 26636067 DOI: 10.3389/Fpubh.2015.00271 |
0.056 |
|
| 2009 |
De Bernardi B, Gerrard M, Boni L, Rubie H, Cañete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B, Couturier J, Ellershaw C, Munzer C, Bruzzi P, ... ... Pearson AD, et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1034-40. PMID 19171711 DOI: 10.1200/JCO.2008.17.5877 |
0.053 |
|
| 2007 |
Łastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C, Roberts P, Hall AG, Tweddle DA, Pearson AD, Lewis I, Burchill SA, Jackson MS. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene. 26: 7432-44. PMID 17533364 DOI: 10.1038/sj.onc.1210552 |
0.051 |
|
| 2013 |
Veal GJ, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, Daly AK, Pearson AD, Boddy AV. Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 469-79. PMID 23087409 DOI: 10.1158/1078-0432.CCR-12-2225 |
0.051 |
|
| 2002 |
Lusher ME, Lindsey JC, Latif F, Pearson AD, Ellison DW, Clifford SC. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Research. 62: 5906-11. PMID 12384556 |
0.05 |
|
| 2013 |
Kirby C, Ambros PF, Billiter D, London WB, Mendonca E, Monclair T, Pearson AD, Cohn SL, Volchenboum SL. Development of an open-source, flexible framework for complex inter-institutional disparate data sharing and collaboration. Amia Joint Summits On Translational Science Proceedings Amia Summit On Translational Science. 2013: 103. PMID 24303312 |
0.048 |
|
| 2013 |
Morris O, Tebruegge M, Pallett A, Green SM, Pearson AD, Tuck A, Clarke SC, Roderick P, Faust SN. Clostridium difficile in children: a review of existing and recently uncovered evidence. Advances in Experimental Medicine and Biology. 764: 57-72. PMID 23654056 DOI: 10.1007/978-1-4614-4726-9-4 |
0.045 |
|
| 2007 |
Cole M, Price L, Parry A, Picton S, Waters F, Marshall S, Goran C, Parnham A, Wastell H, Reid MM, Pearson AD, Boddy AV, Veal GJ. A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer. Pediatric Blood & Cancer. 48: 687-95. PMID 16676305 DOI: 10.1002/pbc.20873 |
0.043 |
|
| 2008 |
Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. The Lancet. Oncology. 9: 247-56. PMID 18308250 DOI: 10.1016/S1470-2045(08)70069-X |
0.042 |
|
| 2016 |
Jerome NP, Miyazaki K, Collins DJ, Orton MR, d'Arcy JA, Wallace T, Moreno L, Pearson AD, Marshall LV, Carceller F, Leach MO, Zacharoulis S, Koh DM. Repeatability of derived parameters from histograms following non-Gaussian diffusion modelling of diffusion-weighted imaging in a paediatric oncological cohort. European Radiology. PMID 27003140 DOI: 10.1007/s00330-016-4318-2 |
0.042 |
|
| 2002 |
Łastowska M, Cotterill S, Bown N, Cullinane C, Variend S, Lunec J, Strachan T, Pearson AD, Jackson MS. Breakpoint position on 17q identifies the most aggressive neuroblastoma tumors. Genes, Chromosomes & Cancer. 34: 428-36. PMID 12112532 DOI: 10.1002/gcc.10089 |
0.04 |
|
| 2005 |
Louis VR, Gillespie IA, O'Brien SJ, Russek-Cohen E, Pearson AD, Colwell RR. Temperature-driven Campylobacter seasonality in England and Wales. Applied and Environmental Microbiology. 71: 85-92. PMID 15640174 DOI: 10.1128/Aem.71.1.85-92.2005 |
0.037 |
|
| 2020 |
Saran R, Pearson A, Tilea A, Shahinian V, Bragg-Gresham J, Heung M, Hutton DW, Steffick D, Zheng K, Morgenstern H, Gillespie BW, Leichtman A, Young E, O'Hare AM, Fischer M, et al. Burden and Cost of Caring for US Veterans With CKD: Initial Findings From the VA Renal Information System (VA-REINS). American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. PMID 32890592 DOI: 10.1053/J.Ajkd.2020.07.013 |
0.037 |
|
| 2014 |
Meany HJ, London WB, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatric Blood & Cancer. 61: 1932-9. PMID 25044743 DOI: 10.1002/pbc.25134 |
0.036 |
|
| 2015 |
Miyazaki K, Jerome NP, Collins DJ, Orton MR, d'Arcy JA, Wallace T, Moreno L, Pearson AD, Marshall LV, Carceller F, Leach MO, Zacharoulis S, Koh DM. Demonstration of the reproducibility of free-breathing diffusion-weighted MRI and dynamic contrast enhanced MRI in children with solid tumours: a pilot study. European Radiology. PMID 25773937 DOI: 10.1007/s00330-015-3666-7 |
0.033 |
|
| 2012 |
Schleiermacher G, Mosseri V, London WB, Maris JM, Brodeur GM, Attiyeh E, Haber M, Khan J, Nakagawara A, Speleman F, Noguera R, Tonini GP, Fischer M, Ambros I, Monclair T, ... ... Pearson AD, et al. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. British Journal of Cancer. 107: 1418-22. PMID 22976801 DOI: 10.1038/Bjc.2012.375 |
0.024 |
|
| 2003 |
Scott DK, Board JR, Lu X, Pearson AD, Kenyon RM, Lunec J. The neuroblastoma amplified gene, NAG: genomic structure and characterisation of the 7.3 kb transcript predominantly expressed in neuroblastoma. Gene. 307: 1-11. PMID 12706883 |
0.023 |
|
| 2009 |
Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 298-303. PMID 19047290 DOI: 10.1200/Jco.2008.16.6876 |
0.021 |
|
| 2009 |
Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 289-97. PMID 19047291 DOI: 10.1200/JCO.2008.16.6785 |
0.015 |
|
| 2009 |
Bagatell R, Beck-Popovic M, London WB, Zhang Y, Pearson AD, Matthay KK, Monclair T, Ambros PF, Cohn SL. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 365-70. PMID 19047282 DOI: 10.1200/JCO.2008.17.9184 |
0.014 |
|
| 2022 |
Chen S, Slowey M, Ashby VB, Barnes L, Pearson A, Kang J, Messana JM. Nursing Home Status Adjustment for Standardized Mortality and Hospitalization in Dialysis Facility Reports. Kidney Medicine. 5: 100580. PMID 36712314 DOI: 10.1016/j.xkme.2022.100580 |
0.012 |
|
| 2021 |
Dahlerus C, Segal J, He K, Wu W, Chen S, Shearon T, Sun Y, Pearson A, Li X, Messana J. Acute Kidney Injury Requiring Dialysis and Incident Dialysis Patient Outcomes in US Outpatient Dialysis Facilities. Clinical Journal of the American Society of Nephrology : Cjasn. PMID 34045300 DOI: 10.2215/CJN.18311120 |
0.012 |
|
| 2014 |
Viprey VF, Gregory WM, Corrias MV, Tchirkov A, Swerts K, Vicha A, Dallorso S, Brock P, Luksch R, Valteau-Couanet D, Papadakis V, Laureys G, Pearson AD, Ladenstein R, Burchill SA. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1074-83. PMID 24590653 DOI: 10.1200/JCO.2013.53.3604 |
0.011 |
|
| 2016 |
Pearson A. Starting out - Do not write off a placement before you've given it a chance. Nursing Standard (Royal College of Nursing (Great Britain) : 1987). 30: 29. PMID 27275900 DOI: 10.7748/ns.30.40.29.s30 |
0.01 |
|
| 2016 |
Adamson PC, Park JR, Pearson AD. When Life Expectancy is Not Short Enough: A Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab. Pediatric Blood & Cancer. PMID 26740172 DOI: 10.1002/pbc.25891 |
0.01 |
|
| 2014 |
Mossé YP, Deyell RJ, Berthold F, Nagakawara A, Ambros PF, Monclair T, Cohn SL, Pearson AD, London WB, Matthay KK. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatric Blood & Cancer. 61: 627-35. PMID 24038992 DOI: 10.1002/pbc.24777 |
0.01 |
|
| 2011 |
Burford NK, Thurrot J, Pearson AD. Minimum energy- maximum space: Higher-density attached family housing Open House International. 36: 62-73. |
0.01 |
|
| 2008 |
Shepley MG, Pearson AD, Smith GD, Banton CJ. The impacts of coal mining subsidence on groundwater resources management of the East Midlands Permo-Triassic Sandstone aquifer, England Quarterly Journal of Engineering Geology and Hydrogeology. 41: 425-438. DOI: 10.1144/1470-9236/07-210 |
0.01 |
|
| 2006 |
Onilude OE, Lusher ME, Lindsey JC, Pearson AD, Ellison DW, Clifford SC. APC and CTNNB1 mutations are rare in sporadic ependymomas. Cancer Genetics and Cytogenetics. 168: 158-61. PMID 16843107 DOI: 10.1016/j.cancergencyto.2006.02.019 |
0.01 |
|
| 2005 |
Ismail A, Lamont JM, Tweddle AD, Pearson AD, Clifford SC, Ellison DW. A 7-year-old boy with midline cerebellar mass. Brain Pathology (Zurich, Switzerland). 15: 261-2, 267. PMID 16196393 |
0.01 |
|
| 2004 |
Yule SM, Price L, McMahon AD, Pearson AD, Boddy AV. Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 455-60. PMID 14760065 DOI: 10.1158/1078-0432.CCR-0844-03 |
0.01 |
|
| 2002 |
De Preter K, Speleman F, Combaret V, Lunec J, Laureys G, Eussen BH, Francotte N, Board J, Pearson AD, De Paepe A, Van Roy N, Vandesompele J. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 15: 159-66. PMID 11850545 DOI: 10.1038/modpathol.3880508 |
0.01 |
|
| Hide low-probability matches. |